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Characterization of Circulating Dendritic Cells
in Melanoma: Role of CCR6 in Plasmacytoid
Dendritic Cell Recruitment to the Tumor
Julie Charles1,2,3,4,10, Je´re´my Di Domizio1,2,3,10, Dimitri Salameire1,2,5, Nathalie Bendriss-Vermare6,7,
Caroline Aspord1,2,3, Ramzan Muhammad2,8, Christine Lefebvre9, Joe¨l Plumas1,2,3, Marie-The´re`se Leccia1,2,4
and Laurence Chaperot1,2,3
Dendritic cells (DCs) are central cells in the development of antitumor immune responses, but the number and
function of these cells can be altered in various cancers. Whether these cells are affected during the development
of melanoma is not known. We investigated the presence, phenotype, and functionality of circulating myeloid
DCs (MDCs) and plasmacytoid DCs (PDCs) in newly diagnosed melanoma patients, compared to controls.
The frequencies of PDCs and MDCs were equivalent in melanoma patients as compared with normal subjects. Both
circulating DC subsets were immature, but on ex vivo stimulation with R848 they efficiently upregulated their
expression of costimulatory molecules. We found that circulating DCs from melanoma patients and controls
displayed similar pattern of expression of the chemokine receptors CXCR3, CXCR4, CCR7, and CCR10. Strikingly,
PDCs frommelanoma patients expressed higher levels of CCR6 than control PDCs, and were able to migrate toward
CCL20. Further data showed that CCR6-expressing PDCs were present in melanoma primary lesions, and that CCL20
was produced in melanoma tumors. These results suggest that PDCs andMDCs are functional in melanoma patients
at the time of diagnosis, and that CCL20 may participate to their recruitment from the blood to the tumor.
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INTRODUCTION
During the past decades, there has been a huge increase in
the incidence of cutaneous malignant melanoma among all
the Caucasian populations as well as in the number of death
due to this cancer throughout the world. Overall 5-year
survival is superior to 95% for the patients with localized
tumors of less than 0.75mm in depth, whereas it drops below
40% for localized melanomas with Breslow index superior to
4mm. Such a poor outcome highlights the need to further
develop new therapeutic strategies, among which immu-
notherapy is a promising one.
Melanoma cells are sensitive to lysis by cytotoxic T
lymphocytes (CTLs) because they express immunogenic
tumor-associated antigens, such as Melan A, gp100, tyrosi-
nase, and Mage3 (Boon et al., 2006), and this property
provides basis for vaccine development. Besides vaccination
with tumor-associated antigens (with or without dendritic
cells (DCs)) (Rosenberg et al., 2004) and treatments based
on adoptive transfer of antitumor CTL (Rosenberg and
Dudley, 2004), the most common immunotherapy used
in melanoma is the injection of interferon (IFN)-a.
Therapeutic efficiency of IFN-a relies both on its direct
antitumor effect and its ability to enhance the immune
responses. IFN-a can be proposed as an adjuvant for the
treatment of malignant melanoma but its use remains
controversial. However, the latest study by the European
Organization for Research and Treatment of Cancer shows
that the adjuvant therapy with pegylated IFN-a-2b has a
beneficial effect on recurrence free-survival in melanoma
patients especially in patients at stage IIIa (Eggermont et al.,
2008). Another way to take advantage of type-I IFNs
antitumor effects could be to induce their endogenous
production by plasmacytoid dendritic cells (PDCs) that
represent a major source of IFN-a in vivo. Indeed, these
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cells secrete huge amounts of IFN-a on recognition of ssRNA
and ssDNA viruses by Toll-like receptor (TLR)7 and TLR9,
respectively (Cella et al., 1999; Siegal et al., 1999). PDCs are
usually detected in the peripheral blood (O’Doherty et al.,
1994) and lymphoid organs (Cella et al., 1999) in the normal
humans whereas in pathological situations such as lupus or
psoriasis they have been found in the inflamed skin producing
type-I IFNs (Farkas et al., 2001; Nestle et al., 2005). Besides
producing IFN-a, activated PDCs also express costimulatory
molecules and secrete other cytokines and chemokines, such
as CXCL10, thus participating in the recruitment of effector
cells of the innate and adaptive immunity (Colonna et al.,
2004; Bendriss-Vermare et al., 2005). Moreover, PDCs similar
to myeloid dendritic cells (MDCs) are able to prime Th1, Th2,
and regulatory T cells (Kadowaki et al., 2000; Moseman et al.,
2004) and can also efficiently stimulate CD8þ T lymphocytes
on appropriate activation (Fonteneau et al., 2003).
In the context of cancer immunotherapy, these properties
suggest that it could be relevant to target PDCs to induce an
endogenous secretion of type-I IFNs as well as an activation
of innate and adaptive immunity. Among the new adjuvants
developed for cancer treatment, CpG ODN and imiquimod
are known to activate PDCs through TLR9 and TLR7,
respectively, showing antitumor effects in clinical trials
(Krieg, 2008; Schon and Schon, 2008). Moreover, along with
others, we have shown that activated PDCs can acquire
cytotoxic functions by expressing the death-inducing ligand
tumor necrosis factor-related apoptosis-inducing ligand on
their surface (Chaperot et al., 2006; Stary et al., 2007). This
killer activity may participate in the antitumor effect of
therapeutic TLR7 or TLR9 agonists. Indeed, the few studies
analyzing the immunological effects of these therapies have
shown PDC activation (Pashenkov et al., 2006; Molenkamp
et al., 2007, 2008), local secretion of IFN-a (Urosevic et al.,
2005), and tumor necrosis factor-related apoptosis-inducing
ligand expression at the treated site (Stary et al., 2007). The
most impressive clinical results have been obtained in the
superficial basal cell carcinoma with complete histological
clearance of the treated tumors in almost 80% of the
cases after topical treatment with imiquimod (Geisse et al.,
2004). In the pilot studies performed in melanoma, such treat-
ment has resulted only in limited regression or stabilization
of lentigo malignant melanoma (Naylor et al., 2003) or
cutaneous melanoma metastasis (Wolf et al., 2003; Zeitouni
et al., 2005). However, to improve the efficiency of these
TLR agonists-based treatments in melanoma, it is necessary
to improve the knowledge of DC functionality and ability to
respond to TLR ligands in this cancer.
The purpose of this study was to characterize circulating
MDCs and PDCs in melanoma patients and to evaluate whether
they are altered or not either quantitatively or qualitatively. We
show the ability of MDCs and PDCs isolated from melanoma
patient’s blood to mature on TLR7/8 triggering in vitro. We also
describe the expression of chemokine receptors by circulating
DC, showing that CCR6 expressed at higher level on PDC from
melanoma patients at the time of diagnosis compared to healthy
individuals could participate to their migration to the tumor site
where CCL20 was produced.
RESULTS
Frequency of circulating PDCs and MDCs is intact in melanoma
patients
Circulating MDC or PDC numbers are modified in various kinds
of pathologies. We first asked whether it could be the case in
melanoma at the time of diagnosis. We analyzed the frequency
of the two main subsets of blood DCs in 22 healthy donors and
43 melanoma patients. A multicolor staining of MDC and PDC
by flow cytometry allows the identification and counting of both
DC subsets among the peripheral blood mononuclear cells
(PBMCs) (Figure 1a). After gating to exclude debris and most
polynuclear cells (Figure 1a, left dot plot), a selection of lineage
(CD3, CD14, CD16, CD19, CD20, and CD56) negative (Linneg)
cells was performed (Figure 1a, middle dot plot). Among these
Linneg cells, PDCs and MDCs were identified as BDCA4þ
CD11c and BDCA4CD11cþ cells, respectively (Figure 1a,
right dot plot), and their respective percentages in PBMCs were
determined. We checked that both subsets of DCs expressed
high levels of HLA-DR molecules and PDCs were BDCA2þ and
CD123hi whereas MDCs were BDCA2 and CD123low (Figure
1b). As shown in Figure 1c, the mean percentage of circulating
MDCs and PDCs in the control individuals was 0.49±0.18 and
0.30±0.17%, respectively. Among PBMCs from melanoma
patients, MDCs represent 0.50±0.23 and PDCs represent
0.29±0.20%. Altogether, these data show that the frequencies
of circulating DC subsets are equivalent in healthy controls and
melanoma patients.
Blood PDCs and MDCs display an immature phenotype in
melanoma patients
To determine whether the quality of DCs could be altered in the
context of melanoma, we then performed a detailed phenotypic
analysis of circulating MDCs and PDCs in the melanoma patients
and healthy controls. A typical expression of costimulatory
molecules by MDCs and PDCs is shown in Figure 2a (for a
control healthy volunteer). Both subsets of DCs expressed neither
CD80 nor CD83, whereas they both expressed CD40 and CD86
(Figure 2b). MDC expressed higher levels of CD40 and CD86
(MFI¼ 34±13 and 37±10, respectively) than PDCs (MFI¼27
±13 and 10±3), and both subsets expressed high levels of
CD62L (data not shown). There were no obvious differences in
costimulatory molecules expression by circulating DCs between
healthy controls and melanoma patients at the time of diagnosis.
As in healthy subjects, both PDCs and MDCs displayed an
immature phenotype in the blood from melanoma patients.
Maturation potential of circulating DCs is maintained in
melanoma patients
To determine whether the ability of immature DC to mature
in melanoma patients remains intact, we performed original
cell culture experiments by adding R848 in the whole blood
samples to activate both PDCs and MDCs through TLR7 and
TLR8, respectively. After 24 hour incubation, we evaluated
the upregulation of molecules associated with DC maturation
on both MDCs and PDCs by multicolor flow cytometry. As
shown in Figure 3, both MDC and PDC highly upregulated
their expression of CD40, CD80, CD83, CD86, and CCR7
after activation with R848. Moreover, Table 1 shows that
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MDCs and PDCs from melanoma patients and healthy
controls matured to the same extend on activation by TLR7/
8 ligand, indicating that circulating DCs retain their ability to
mature in melanoma.
Blood PDCs from melanoma patients express CCR6, a skin
homing receptor, and migrate toward CCL20
To further characterize DCs in the context of melanoma and
try to understand their recruitment in the tumor site, we
analyzed their chemokine receptors expression profile. As
shown in Figure 4a (for a healthy donor), both MDCs and
PDCs expressed high levels of CXCR4 and intermediate levels
of CCR10. As already described, PDCs expressed high levels
of CCR7 and CXCR3 whereas MDCs were CCR7low and
CXCR3low. As shown in Figure 4b, there were no differences
between circulating MDCs and PDCs regarding CXCR3,
CXCR4, CCR7, and CCR10 expression between the healthy
controls and melanoma patients.
MDC
PDC
CD
11
c
BD
CA
4
IgG1 HLA-DR BDCA2
CD
11
c
BDCA4FSC FSC
SS
C
Li
n
MDC
0.4 %
PDC
0.3 %
MDC
Control Mel D
0.0
0.5
1.0
1.5
PB
M
C 
(%
)
0.0
0.5
1.0
1.5
PB
M
C 
 (%
)
N = 20
PDC
NS NS
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105104103102
105104103102 105104103102 105104103102 105104103102
105104103102 105104103102 105104103102
104
103
102
101
100
104
103
102
101
100
104103102101100
1,000
800
600
400
200
0
0 200 400 600 800 1,000 0 200 400 600 800 1,000
CD123
N = 41
Control Mel D
N = 20 N = 43
Figure 1. Frequencies of circulating plasmacytoid dendritic cells (PDCs) and myeloid dendritic cells (MDCs) in melanoma patients and healthy donors are
equivalent. Dendritic cell subsets were identified and quantified by flow cytometry. (a) Identification of MDCs (CD11cþ /BDCA4neg) and PDCs (CD11c/
BDCA4þ ) (right dot plot) within whole blood mononuclear (left dot plot) lineage negative (middle dot plot) cells. Numbers indicate the percentages of PDCs and
MDCs within peripheral blood mononuclear cells. (b) Representative phenotype of MDCs and PDCs taken from one of the control healthy volunteers. (c) The
frequencies of MDCs (left panel) and PDCs (right panel) in the peripheral blood of melanoma patients and healthy controls are shown. (Horizontal bars represent
mean percentages.)
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Strikingly, while analyzing CCR6 expression, we found
that circulating PDCs from some melanoma patients
expressed higher levels of CCR6 as compared to PDCs from
healthy donors (Figure 5a). To go further, we increased the
number of melanoma patients in our study for CCR6
expression by PDCs in the two defined groups. As shown in
Figure 5b, significantly higher CCR6 levels (Po0.005,
Mann–Whitney U-test) were detected on circulating PDCs
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Figure 2. Circulating dendritic cells from melanoma patients display an immature phenotype. (a) Representative comparative phenotype of myeloid dendritic
cells (MDCs) (CD11cþ , upper row of dot plots) and plasmacytoid dendritic cells (PDCs) (BDCA4þ , lower row of dot plots) from one of the healthy controls.
(b) Expression of the activation/maturation markers by MDCs and PDCs from melanoma patients (black bars, n¼34) and healthy controls (white bars, n¼ 15).
Mean percentages and standard deviation are shown.
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Figure 3. Activation profiles of circulating myeloid dendritic cells (MDCs) and plasmacytoid dendritic cells (PDCs) in response to TLR7/8 ligand. Evaluation of
activated MDC (Linneg, CD11cþ ) and PDC (Linneg, BDCA2/BDCA4þ , CD11c) after 24-hour culture of whole blood with R848. The expression of CD40,
CD80, CD83, CD86, and CCR7 is increased on both dendritic cell (DC) subsets after culture with R848 (dark gray) as compared to control culture (light gray).
Representative graph was taken from a healthy control.
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from melanoma patients (mean: 34±21% of positive cell) as
compared to healthy controls (16±8%). CCR6 was expressed
by more than 40% of circulating PDCs in 15 out of 41
melanoma patients (36%), which was never the case in the
control group. There was no significant difference between
stages I–II and stages III–IV and in both groups, the level of
CCR6 expression on PDC was higher compared to healthy
donors group (data not shown). In contrast, no difference was
observed in the expression levels of CCR6 on MDCs in the
two groups (52±17 and 55±18%). These results suggest that
CCR6 is specifically upregulated on circulating PDCs in
melanoma patients.
To evaluate the capacity of CCR6-expressing PDCs from
melanoma patients to migrate in response to CCL20, we
performed migration experiments. Whole PBMCs from five
patients and seven healthy donors were used in Transwell
assays. The cells that were recovered in the lower chamber
were counted by flow cytometry to precisely determine the
number of PDCs and MDCs responding to CCL20 or CXCL12.
As expected and shown in Figure 5c, both PDCs and MDCs
highly migrated toward CXCL12, with more than 70% of the
cells initially put in the upper chamber of the well migrating in
the lower chamber. MDCs from healthy donors and melanoma
patients migrated in response to CCL20, with, respectively,
18±2 and 20±5% of the MDCs migrating. PDCs from healthy
donors that expressed low levels of CCR6 (mean¼16±6%,
data not shown) did not migrate toward CCL20. Conversely,
PDCs from melanoma patients chosen for their high expression
of CCR6 (mean¼ 55±15%, data not shown) displayed a slight
but statistically significant (Po0.05) migration in response to
CCL20, with 8±3% of the PDCs initially put in the well
migrating, compared to 3±2% in the control condition. These
experiments show the functionality of CCR6 expressed by
circulating PDCs from melanoma patients.
CCR6þ PDC infiltrate melanoma tumors where CCL20
is produced by melanoma cells
We investigated whether CCR6þPDC could be detected in
the primary melanoma tumors by immunohistochemistry and
immunofluorescence. By using BDCA2, a specific marker for
PDCs, we detected PDCs in 10 (37%) out of 27 cases.
BDCA2þ PDCs were located close to the tumor within the
peritumoral leukocyte infiltrate, representing 2–5% of these
cells (data not shown). In six of these cases, we identified
BDCA2þ cells coexpressing CCR6 (representative immuno-
histochemical and immunofluorescence data shown in Figure
6a and b (one case and two cases, respectively, see arrows).
Interestingly, we were able to detect CCL20 in 7 out of 12
fresh melanoma metastasis supernatants (Figure 7a). This
secretion was not an artifact due to the 24-hour culture,
because mRNA coding for CCL20 was detected in fresh
melanoma tumors by RTqPCR (Figure 7b). Altogether these
data suggest that CCL20 is produced in the tumor micro-
environment and might be involved in the recruitment of
CCR6þ PCD in the melanoma tumors.
DISCUSSION
DCs are central cells in the development of antitumor
T cell responses. However, the relative contribution of PDCs
and MDCs to antitumor immune responses is still a matter of
debate. Innovative cancer immunotherapeutic strategies
targeting DCs in vivo are currently under development, but
their efficacy will directly rely on the availability of functional
DCs. This study focused on phenotype and functionality of
the circulating DCs in melanoma patients.
Equivalent frequencies of circulating MDCs and PDCs were
found in the healthy controls and melanoma patients, contrarily
to what has been described in other pathologies including
cancers. Indeed, a decrease in the blood MDC and PDC
frequencies has been described during the course of various
kinds of hematological malignancies (Mohty et al., 2002; Ratta
et al., 2002; Boissel et al., 2004; Mami et al., 2004). In these
cases, low DC counts might be due to an alteration of
‘‘dendritopoiesis’’ during the disease progression. Elsewhere, in
Table 1. R848-induced activation and maturation
of PDCs and MDCs in melanoma patients and
healthy donors
Controls (n=7) Melanoma patients (n=12)
PDCs MDCs PDCs MDCs
CD40
T0 86 (8) 67 (13) 77 (10) 71 (13)
24 hours medium 79 (3) 94 (2) 75 (20) 97 (4)
24 hours R848 94 (9) 98 (3) 87 (13) 96 (12)
CD80
T0 6 (6) 5 (3) 7 (5) 9 (5)
24 hours medium 14 (11) 39 (11) 22 (11) 37 (16)
24 hours R848 72 (18) 89 (10) 65 (19) 75 (18)
CD83
T0 8 (9) 5 (4) 7 (2) 7 (2)
24 hours medium 14 (11) 46 (19) 22 (9) 31 (16)
24 hours R848 77 (19) 86 (10) 63 (16) 65 (19)
CD86
T0 56 (16) 96 (2) 53 (16) 83 (5)
24 hours medium 43 (17) 95 (6) 33 (9) 71 (24)
24 hours R848 70 (22) 98 (2) 72 (13) 95 (14)
CCR7 74 (23) 26 (24) 65 (22) 36 (6)
T0
24 hours medium 86 (4) 74 (5) 68 (25) 53 (14)
24 hours R848 98 (3) 72 (29) 81 (24) 77 (9)
Abbreviations: MDC, myeloid dendritic cell; PDC, plasmacytoid dendritic
cell.
Whole blood cells were cultured in the presence of R848 to activate both
MDCs and PDCs. The mean (standard deviation) percentage of positive
cells for each marker was analyzed for MDCs and PDCs in melanoma
patients and controls.
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advanced solid tumors (van Cruijsen et al., 2007), such as
breast cancers (Pinzon-Charry et al., 2007) or hepatocellular
carcinomas (Beckebaum et al., 2004), reduced frequencies of
circulating DCs or their absolute numbers have also been
reported. In these advanced cancers, it has been suggested that
decreased DC numbers are due to systemic tumor-induced
immunosuppression. Our results show that the frequencies of
circulating PDCs and MDCs are not affected in melanoma
patients, suggesting that these cells could be targeted to
stimulate immune responses in these patients.
We next analyzed the functionality of circulating DCs in
melanoma patients. Indeed, abnormalities in the maturation
of MDCs have been found in many kinds of cancers
(reviewed by Gabrilovich (2004)) but very few data are
available regarding the functionality of PDCs. By analyzing
the expression of costimulatory molecules, we found that the
circulating MDCs and PDCs from melanoma patients were
very similar to that of healthy donors and were immature.
Furthermore, on in vitro activation with R848, a TLR7/8
agonist, both MDCs and PDCs from melanoma patients
matured as efficiently as MDCs and PDCs from healthy
volunteers. These data show that the circulating DCs in
melanoma patients have retained their ability to respond to
TLR ligands, which is encouraging for the development of
alternative treatments based on TLR7 or TLR9 agonists.
Although these molecules are still early in their clinical
development (Krieg, 2008; Schon and Schon, 2008), they
seem efficient regarding skin cancers. We have recently
shown that PDCs produce IFN-a and express tumor necrosis
factor-related apoptosis-inducing ligand on activation
(Chaperot et al., 2006), suggesting that they may participate in
the efficacy of imiquimod. In the basal cell carcinomas treated by
topical application of imiquimod, it has been shown that PDCs
are recruited in the tumor site (Urosevic et al., 2005; Stary
et al., 2007) along with other immune cells. The mechanisms
leading to this recruitment are still poorly understood.
MDCs are constitutively recruited into the skin epithelium
by CCR6 whereas PDCs are not found in this peripheral tissue
under steady-state conditions. However, PDCs accumulate in
the cutaneous lesions of systemic lupus erythematosus
(Farkas et al., 2001) or psoriasis (Nestle et al., 2005) where
they secrete IFN-a. The recruitment of PDCs in such
inflammatory contexts has been suggested to depend on
CXCR3 in synergy with CXCR4 (Vanbervliet et al., 2003;
Lande et al., 2004) or on ChemR23 (Vermi et al., 2005). PDCs
have also been found in the infiltrate of some kinds of tumors,
including carcinomas of the head and neck (Hartmann et al.,
2003), breast (Treilleux et al., 2004), lung (Perrot et al., 2007),
MDC
PDC
CD
11
c
BD
CA
4
CXCR3
CXCR3 CXCR4 CCR7 CCR10
0
20
40
60
80
100 Control
Mel D
Po
si
tiv
e 
ce
lls
 (%
)
MDC
CXCR3 CXCR4 CCR7 CCR10
0
20
40
60
80
100
Po
si
tiv
e 
ce
lls
  (%
)
PDC
CCR10CCR7CXCR4
105104103102
105104103102 105104103102 105104103102 105104103102
105104103102 105104103102 105104103102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
105
104
103
102
Figure 4. Expression of chemokine receptors by circulating dendritic cells from melanoma patients. (a) Representative expression of chemokine receptors
by myeloid dendritic cells (MDCs) (CD11cþ , higher dot plots) and plasmacytoid dendritic cells (PDCs) (BDCA4þ , lower dot plots) (taken from one of the
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Figure 6. Detection of CCR6-expressing plasmacytoid dendritic cells (PDCs) in melanoma microenvironment. (a) BDCA-2þ PDCs (brown) can be seen in the
peritumoral area among the infiltrating leucocytes in melanoma (original magnification  20, bar¼ 100mm). High magnification of the three insets shows
CCR6-expressing PDCs (green) (original magnification 64, bar¼ 10mm). (b) BDCA2þ PDC (red) were also detected by immunofluorescence in primary
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#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12
1
10
100
1,000
M
IP
3α
 
(pg
 m
l–1
)
K562 ME275 #3 #5 #8 #10
0.001
0.01
0.1
1
10
CC
L2
0 
(re
lat
ive
 C
t)
Figure 7. Detection of CCL20 in melanoma tumers. (a) Measurement of CCL20 secretion in 12 supernatants of melanoma metastasis taken after 24 hours of
culture. (b) Detection of CCL20 mRNA by quantitative RT-PCR in fresh melanoma tissues samples.
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and ovarian cancers (Zou et al., 2001; Curiel et al., 2004).
Our observation confirms the presence of tumor-infiltrating
PDCs in melanoma (Salio et al., 2003; Vermi et al., 2003).
It has been proposed that melanoma cells attract PDCs by
CXCL12 (Zou et al., 2001; Vermi et al., 2003; Curiel et al.,
2004). We have analyzed the expression of chemokine
receptors by the circulating PDCs and as expected PDCs
expressed CXCR4 that could be involved in their recruitment
to tumor site. Strikingly, circulating PDCs from melanoma
patients expressed higher levels of CCR6 as compared to
healthy volunteers, and were able to migrate toward CCL20.
Moreover, PDCs expressing CCR6 were detected in primary
tumors, and CCL20, a ligand for CCR6, is expressed by
keratinocytes in the skin and also by melanoma cells (Lee
et al., 2003; Movassagh et al., 2004; Hasan et al., 2006)
(Figure 7), suggesting that CCR6/CCL20 could participate in
the migration of PDC from the blood to the tumor. We thus
propose that this CCR6/CCL20 interaction could constitute a
new way of PDC recruitment to primary melanoma.
Interestingly, we have already described the expression and
functionality of CCR6 on leukemic PDC, a kind of malignancy
that frequently develops into the skin (Bendriss-Vermare et al.,
2004). The question of the induction of CCR6 on PDC has to
be further investigated. In this context, Bendriss-Vermare et al.
recently showed that IL-3 is able to upregulate CCR6
expression on primary human PDCs (CCR6 and CCR10
orchestrate human PDC recruitment during anti viral and
bacterial immune defense, article submitted). It remains to
determine whether the mechanism responsible for CCR6
expression by blood PDCs from melanoma patients involves
IL-3 or other factors that could be produced either by the
tumor or by other cells during the development of melanoma.
In the context of melanoma, TLR7 or TLR9 agonist
monotherapies have been used (Pashenkov et al., 2006;
Molenkamp et al., 2007; Dummer et al., 2008). Other studies
have also tested topical application of imiquimod (R837)
(Adams et al., 2008) or subcutaneous injection of PF-
3512676 (CpG 7909) (Speiser et al., 2005) as adjuvant for
vaccination to improve T cell responses. Altogether, our data
encourage the development of such therapeutic strategies
based on the activation of DCs to induce antitumor immune
responses. Indeed, we show here that both MDCs and PDCs
are available, functional, and mobilizable in the early phases
of melanoma development.
MATERIALS AND METHODS
Patients
A total of 71 patients (43 men and 28 women) diagnosed as
cutaneous melanoma were enrolled in the study. Fresh blood
samples were obtained from 43 patients in the 3 weeks after the
initial diagnosis of melanoma before the wide local excision of the
primary lesion and any complementary surgical or medical
treatment. Thirty-three patients were at stage I–II according to the
American Joint Committee on Cancer classification (Balch et al.,
2001), nine were in stage III (according to lymph node analysis), and
one was at stage IV (pulmonary metastasis were present at the time
of initial staging). Fresh blood samples of 22 healthy controls were
also studied. Twenty-nine confirmed primary cutaneous melanoma
samples were screened for immunohistology analysis. Tumor super-
natants were obtained from 12 fresh metastatic tumor samples. The
mean age of the patients at sampling time was 58 years (ranging from
21 to 87). Approval to conduct the study was given by the Comite´ de
Protection des Personnes of the Centre Hospitalo-Universitaire de
Grenoble. The Declaration of Helsinki Principles were followed and
all participants gave their written consent to take part.
Antibodies and flow cytometry
Immunophenotyping was performed by flow cytometry on
a FACScan or FACScalibur (BD Biosciences, Mountain View,
CA), using direct and indirect labeling. Monoclonal antibodies
conjugated with biotin, FITC, phycoerythrin (PE), PECy-5, or
antigen-presenting cell (APC) were used. Anti-lineage Cocktail 1
(Lin1, a mix of CD3, CD14, CD16, CD19, CD20, and CD56), -
CD11c, and -CD123 (9F5) antibodies were obtained from Becton
Dickinson (San Jose, CA). Anti-BDCA2 (AC144) and anti-BDCA-4
(AD5-17F6) were purchased from Miltenyi Biotec (Bergisch Glad-
bach, Germany). PE-conjugated Control IgG1 (679.1Mc7), anti-HLA-
DR (B8.12.2), streptavidin, CD40 (HIT2), CD45RO (UCHL1), CD62L
(Dreg46), CD80 (MAB104), CD83 (HB15A), CD86 (HA5.2B7), Goat
F(ab’) 2 Fragment anti-mouse IgM, and purified IgM (GC323) were
obtained from Immunotech (Marseille, France). Goat F(ab’) 2 anti-
rabbit IgG antibodies was purchased from Caltag Laboratories,
Burlingame, CA; PE-conjugated-anti-CCR6 (11A9), anti-CXCR3
(1C6), anti-CXCR4 (12G6), and purified anti-CCR7 (2H4) antibodies
were purchased from Pharmingen (San Diego, CA). Purified anti-
CCR10 antibody was from IMGENEX (San Diego, CA).
Enumeration and phenotyping of DCs
Blood DCs were identified by multicolor staining performed on
whole blood. Briefly, 200 ml heparinized blood was used for each
staining tube. Cells were incubated for 20minutes at room
temperature with FITC-Lin1, APC-CD11c, and biotinylated-anti-
BDCA4, washed, and then further incubated for 20minutes with
PeCy-5-streptavidin. Red cell lysis was performed by the addition of
2ml of FACSLysing solution (Becton Dickinson) for 10minutes
according to manufacturer’s instructions. After washing with
phosphate-buffered saline, cells were acquired by flow cytometry.
At least 2 105 PBMCs were acquired according to the forward light
scatter versus side light scatter profile. Among Linneg cells, MDCs
were recognized as CD11cþ /DCA4neg cells whereas PDCs were
CD11cneg/BDCA4þ , and their respective percentages among
PBMCs were determined.
For surface marker analysis of costimulatory molecules or
chemokine receptor expression, PE-conjugated monoclonal anti-
bodies were added to the previously described cocktail that allowed
the differential analysis of PDC and MDC phenotype.
Activation of PBMCs
Whole blood samples (2ml) from healthy donors and melanoma
patients were cultured for 24 hours with or without 1 mgml1 of
R848 (TLR7/8 ligand), (Invivogen, San Diego, CA). Blood samples
were then handled as previously described and immunostained for
the following activation markers: CD40, CD80, CD83, CD86, or
CCR7. Each marker was associated with PE-labeling and the cocktail
of FITC-Lin, biotinylated-BDCA-2þ /biotinylated-BDCA-4, APC-
CD11c, followed by labeling with PeCy-5-streptavidin. At least
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2 105 PBMCs were acquired by flow cytometry. Among Linneg
cells, MDCs were recognized as CD11cþ cells whereas PDCs were
CD11cneg/BDCA2þ /BDCA4þ , and their respective expression of
activation markers was determined.
Chemotaxis assay in Transwells
Migration assays were carried out using Transwells (6.5mm
diameter; COSTAR, Cambridge, MA) with 5 105 cells per well.
Fresh PBMCs were washed, preincubated for 1 hour at 37 1C in RPMI
medium, fetal calf serum 2% with IL-3 (10 ngml1), and then placed
for 2 hours in 5 mm pore size inserts at 37 1C. The migrating cells were
harvested, immunostained with Lin-FITC/BDCA4-PE/HLA-DR-PC5,
and counted by flow cytometry. The results are expressed as the
percentage of MDCs (Linneg/BDCA4neg/HLA-DRþ ) and PDCs (Linneg/
BDCA4þ /HLA-DRþ ), which have migrated related to the input
number of DCs. The chemokines used were CCL20 and CXCL12 at
1000ngml1 (R&D systems, Minneapolis, MN).
Histology
Immunohistochemistry. Alcohol/formalin/acetic acid-fixed and
paraffin-embedded surgical specimens from 13 cases of confirmed
melanoma were cut at 3mm, deparaffinized, and pretreated in Tris
citrate buffer (pH¼ 8, 100 1C, 30minutes). A double immunostain-
ing was performed. In brief, nonspecific sites were blocked by
donkey serum (2%, 30minutes, room temperature). The first anti-
BDCA2 antibody (clone 104C12; Dendritics, Dardilly, France) was
incubated at room temperature overnight at the dilution of 1:25. The
sections were incubated with biotinylated-donkey anti-mouse IgG
for 60minutes, then treated with peroxydase-conjugated avidin/
biotin complex (Zymed Laboratories, San Francisco, CA; Histostain
Plus Bulk Kit) and followed by immunodetection with diaminobenzi-
dine. After heating antigen retrieval with citrate buffer (pH¼ 6,
30minutes, 100 1C), the sections were sequentially incubated with
the second anti-CCR6 antibody (clone 53103; R&D Systems) at the
dilution of 1:200 for overnight at room temperature, followed by
secondary staining with biotinylated-donkey anti-mouse IgG for
60minutes, peroxydase-conjugated avidin/biotin complex, and re-
vealed by Histogreen Peroxydase Substrate (Vector laboratories,
Burlingame, CA). Control included the omission of the first primary
antibody in the second immunolabeling step.
Immunofluorescence. Alcohol/formalin/acetic acid-fixed and
paraffin-embedded surgical specimens cut at 3 mm from four cases
of confirmed melanoma were used. Double immunostaining with
BDCA2 and CCR6 was performed. The anti-BDCA2-Alexa-Fluor 546
antibody (clone 104C12, dilution 1:25; Dendritics) and the CCR6-
FITC antibody (clone 53103; R&D Systems; dilution 1:100) were
incubated at room temperature overnight after a pretreatment in Tris
citrate buffer (pH¼ 8, 100 1C, 30minutes). The sections were
counterstained with DAPI and observed on a Zeiss (Hallbergmoos,
Germany) Axioimager M1 microscope.
Detection of CCL20 chemokine in tumors
ELISA. Melanoma supernatants were obtained from 12 cutaneous
or nodal metastases. In brief, fresh tumor samples were dila-
cerated and digested in collagenase (Roche Diagnostics, Manheim
Germany). The cell suspension was seeded at the concentration
of 1 106 cells per ml. Then, the supernatant was recovered after
24 hours. The concentrations of CCL20 were measured by ELISA
(R&D Systems).
Quantitative RT-PCR. In four cases, a part of the fresh cell
suspension was frozen and used for RTqPCR detection of CCL20
mRNA. Total RNA was isolated using RNeasy kit (Qiagen, Courta-
boeuf, France). Reverse transcription to cDNA was carried out by
standard methods using reverse transcriptase (Roche Diagnostics,
Meylan, France) and dNTP (Roche Diagnostics). These cDNA were
amplified using naked primers, LightCycler TaqMan Master mix
and Universal ProbeLibrary probe (Roche Diagnostics). PCRs
were conducted in a LightCycler instrument (Roche Diagnostics).
Primers were synthesized by Roche Diagnostics, their sequences
were as follows (listed 50-30): G6PDH (F, aacagagtgagcccttcttca;
R, ggaggctgcatcatcgtact); human CCL20 (F, gctgctttgatgtcagtgct; R,
tcaaagttgcttgctgcttc). Relative threshold cycle (Ct) values for each gene
were normalized to the housekeeping gene G6PDH using the equation
2(dCp), where Cp is the mean cross point of duplicate runs calculated
by LightCycler software and dCp¼ gene CpG6PDH Cp.
Statistical analysis
The Mann–Whitney U-test was used for the comparisons between
independent groups. The student’s t-test was used to compare the
average migrations of DCs toward chemokines.
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